We Once Were Blind and Now We See: Is it Time to Treat Ulcerative Colitis to Achieve Mucosal Healing?

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 6, 2011, Pages 456-457

  Rubin, David T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLON RESECTION; CROHN DISEASE; DISEASE SEVERITY; EDITORIAL; HEALING; HOSPITALIZATION; HUMAN; INTESTINE ENDOSCOPY; INTESTINE MUCOSA; MUCOSAL HEALING; PROGNOSIS; REMISSION; SEX DIFFERENCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DRUG MONITORING; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; PROGNOSIS; TREATMENT OUTCOME;

EID: 79957458678     PISSN: 15423565     EISSN: 15423565     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.03.009     Document Type: Editorial

References (12)

1. Rutgeerts P., Vermeire S., Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut 2007, 56:453-455.
2. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:483-489.
3. Gupta R.B., Harpaz N., Itzkowitz S., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105. quiz, 1340-1341.
4. Rutter M., Saunders B., Wilkinson K., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
5. Soderlund S., Granath F., Broström O., et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010, 138:1697-1703.
6. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
7. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
8. Baert F., Moortgat L., Van Assche G., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468. quiz, e10-e11.
9. Kamm M.A., Sandborn W.J., Gassull M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007, 132:66-75. quiz, 432-433.
10. Lichtenstein G.R., Ramsey D., Rubin D.T. Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011, 33:672-678.
11. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
12. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137:1250-1260. quiz, 1520.